Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat

Contributed by: PR Newswire

Tags

Enzymatica-AB

More Like This

New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms

ColdZyme® certified under the new EU medical device regulation (MDR)

Enzymatica AB - Interim report Q3/2023: Research results that reshape the competitive landscape

Nasal Spray VIRALEZE™ For Respiratory and Cold Viruses, Including New Strains

Enzymatica Interim report Q1/2024: MDR certification opens up great commercial opportunities

Enzymatica AB: Invitation to Press Briefing - 5 March 2025

Professor Sebastian Johnston

Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials

Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new markets